“Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s83. doi:10.25251/skin.4.supp.83.